Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Phase 3positiveavexitidePositive
AI Analysis
Summary
Amylyx Pharmaceuticals announced positive topline results from its Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, meeting the FDA-agreed primary endpoint with a 55% reduction in hypoglycemic events versus placebo and meeting all secondary endpoints.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
LUCIDITY met FDA-agreed-upon primary endpoint with 55% reduction in composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003); all secondary endpoints met
Importance:8/10
Sentiment:
0.90
Phase 3 datapositive resultshypoglycemiarare disease
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on August 18, 2026 8:08 PM